Innovation in biotechnology, particularly within the realm of cell therapy, hinges significantly on the expertise of regulatory professionals. These experts are instrumental in navigating complex regulatory landscapes and ensuring that scientific advances transition into viable, market-ready
The field of spinal muscular atrophy (SMA) treatment has been dynamically evolving, and the latest breakthrough stems from Scholar Rock's Phase 3 clinical trial of apitegromab. This experimental drug is designed to preserve muscle function, representing a potential new standard of care for SMA
The controversy surrounding Cassava Sciences and its experimental Alzheimer's drug, simufilam, has garnered significant attention within the medical and research communities, as well as among regulatory bodies and patient advocacy groups. Allegations of data manipulation and scientific misconduct
Biopharmaceutical companies face numerous challenges in the quest to develop and commercialize effective oncology drugs. The intricate journey from Phase 1 trials to market approval often sees only a small fraction of drugs succeeding, and even when they do, understanding how new drug approvals
Patient recruitment for clinical trials in the biopharma industry is often a challenging task. Successful recruitment strategies can significantly impact the efficiency and effectiveness of clinical trials, ultimately contributing to bringing new therapies to market faster. To achieve this,
Zephyrm Bioscience has announced its intention to pursue an initial public offering (IPO) on the Hong Kong stock exchange. The biotech company aims to secure significant funding to advance its lead cell therapy candidate, ZH901, into phase 3 clinical trials. ZH901 is targeted at treating both a
